Delayed Benefit From Aggressive Immunotherapy in Waxing and Waning Anti-IgLON5 Disease

Anti-IgLON5 disease is a rare disorder characterized by the variable association of movement disorders, sleep disturbances, cognitive impairment, bulbar symptoms, and respiratory dysfunction.1,2 Pathophysiology likely involves both autoimmune and neurodegenerative processes, and prognosis is considered to be poor.3,4 Here, we report a case with a waxing and waning course, who eventually responded well to aggressive and sustained immunotherapy.